{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015838","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.416561+00:00","generated_at":"2026-06-10T15:09:02.161658+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Virios Therapeutics terminates at-the-market sales agreement with JonesTrading","bullets":["Sales agreement terminated effective Sept 28, 2023; no sales since Aug 9, 2023; up to $6.7M capacity.","Company faces no termination penalties.","Focus shifts to operational priorities: second Long-COVID study of IMC-2, non-dilutive funding, FDA meeting.","CEO Greg Duncan cites current market conditions as rationale.","Pre-IND meeting planned with FDA for IMC-2 in Long-COVID and fatigue disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015838","json":"https://secwatch.observer/filing/0001558370-23-015838.json","markdown":"https://secwatch.observer/filing/0001558370-23-015838.md","text":"https://secwatch.observer/filing/0001558370-23-015838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023015838/0001558370-23-015838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023015838/tmb-20230918x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T15:09:02.161658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9dcaaab4b5e7c97fb0b6f1c7d059a56838da111","claim":"Dogwood Therapeutics, Inc. terminated Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC valued at up to $6,700,000 (effective 2023-09-28).","evidence_excerpt":"On September 18, 2023, Virios Therapeutics, Inc. (the “Company”) provided notice of its termination, effective September 28, 2023, of the Capital on Demand Sales AgreementTM, dated July 14, 2023 (the “Sales Agreement”), by and between the Company and JonesTrading Institutional Services LLC (“JonesTrading”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023015838/0001558370-23-015838-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"JonesTrading Institutional Services LLC"},{"label":"Value","value":"up to $6,700,000"},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}